Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis
Philippe Lehert, Efstratios M Kolibianakis, Christos A Venetis, Joan Schertz, Helen Saunders, Pablo Arriagada, Samuel Copt, Basil Tarlatzis
Reproductive Biology and Endocrinology | BMC | Published : 2014
BACKGROUND: The potential benefit of adding recombinant human luteinizing hormone (r-hLH) to recombinant human follicle-stimulating hormone (r-hFSH) during ovarian stimulation is a subject of debate, although there is evidence that it may benefit certain subpopulations, e.g. poor responders. METHODS: A systematic review and a meta-analysis were performed. Three databases (MEDLINE, Embase and CENTRAL) were searched (from 1990 to 2011). Prospective, parallel-, comparative-group randomized controlled trials (RCTs) in women aged 18-45 years undergoing in vitro fertilization, intracytoplasmic sperm injection or both, treated with gonadotrophin-releasing hormone analogues and r-hFSH plus r-hLH or ..View full abstract
This systematic review and meta-analysis was supported by Merck Serono S. A. - Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany. The authors thank Jocelyn Woodcock of Caudex Medical, Oxford, UK (supported by Merck Serono S.A. - Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany), for her assistance in the preparation of this manuscript.